Mainland China Funds Accumulate HK Biotech Stakes as Licensing Deal Wave Spurs Rerating

The Quick Take

• Mainland Chinese institutional fund managers have built up stakes in Hong Kong-listed biotech stocks over the past month, attracted by depressed valuations and surging cross-border licensing activity.
• A wave of licensing deals between HK-listed Chinese biotech firms and global multinational pharmaceutical companies is underpinning investor conviction in the sector's rerating potential.
• Attractive valuations relative to global biotech peers have created an opportunity window, especially as HK's biotech listing rules allow pre-revenue companies to trade on pipeline rather than earnings.

Mainland Chinese institutional investors have markedly increased their holdings in Hong Kong-listed biotechnology stocks over the past month, according to South China Morning Post analysis, as a surge in cross-border drug licensing deals validates the commercial potential of domestically developed oncology and immunology pipelines. This buying activity reflects a shift in mainland capital allocation strategy — moving away from purely domestic A-share biotech positions toward HK-listed counterparts whose valuations remain at a significant discount to both global peers and their intrinsic pipeline value. The licensing deal wave signals that global pharmaceutical majors are actively validating Chinese biotech innovation quality.

The strategic accumulation of HK biotech stakes by mainland funds carries important implications for HKEX's biotech segment, which has struggled with persistent IPO-era valuation compression since 2021-2022. Sustained mainland buying provides a structural demand floor and could catalyze a broader sector rerating if licensing deal momentum continues. For global pharmaceutical companies active in licensing discussions, increased mainland fund presence may raise negotiating costs, as institutional investors take positions ahead of deal announcements. Peers in Singapore and other Asian biotech hubs may also benefit from improved risk appetite for pre-revenue life sciences investments across the region.

Forward signals to watch include the pace of further cross-border licensing deal announcements from HK-listed Chinese biotechs — particularly in oncology and cardiometabolic disease areas — which have attracted the most attention from global pharma partners. Track Southbound Stock Connect flows (mainland investor buying in HK stocks) for confirmation that institutional accumulation is broadening beyond the initial cohort of funds. The macro variable is US-China geopolitical temperature: sustained trade truce and technology de-escalation would accelerate mainland confidence in HK-listed assets; renewed tensions could reverse the accumulation trend quickly.

Synthesized from 1 source.